南方医科大学学报2012，Vol.32Issue(10)：1431-1434,4.DOI:10.3969/j.issn.1673-4254.2012.10.010
重组葎草花粉主要变应原免疫特性研究
Immunological characteristics of the recombinant major pollen allergen pTSX2 of Humulus scandens
摘要
Abstract
Objective To identify the immunological characteristics of the recombinant major pollen allergen pTSX2 of Humulus scandens and evaluate its safety in immunotherapy of allergic asthma in mice. Methods Western blotting was used to characterize the immunological properties of pTSX2, and its immunogenicity in normal mice was evaluated by detecting slgG and slgE levels. The mouse models of allergic asthma were immunized with pTSX2 and examined for slgE and slgG levels, total cells and eosinophils percentage in BALF, interleukin-4 (IL-4) and interferon-y (IFN-y) levels in BALF and spleen homogenate, and changes in lung pathologies. Results Western blotting showed that pTSX2 reacted with the majority (about 70%) of sera from patients allergic to Humulus pollen. In normal mice, pTSX2 mainly induced the production of slgG, In mouse models of allergic asthma, intervention with pTSX2 caused a significant reduction of slgE and an increase of slgG (P< 0,05), significantly decreased the total cells and eosinophils in BALF (P<0.05), obviously lowered IL-4 but increased IFN-γ in BALF and spleen homogenate (P<0.05)/ and diminished inflammatory cell infiltration and percentage of eosinophils in the lung tissues. Conclusion pTSX2 shows a definite therapeutic effect and safety in the treatment of allergic asthma in mice possibly by inhibiting slgE and inducing sIgG production, suppressing airway allergic inflammation and regulating the balance between Thl and Th2.关键词
支气管哮喘/葎草花粉变应原/重组变应原/特异性免疫治疗Key words
bronchial asthma/ humulus pollen allergen/ recombinant allergen/ specific immunotherapy分类
医药卫生引用本文复制引用
吴媛媛,孙秀珍,李满祥,刘昀,王贵佐,卢家美..重组葎草花粉主要变应原免疫特性研究[J].南方医科大学学报,2012,32(10):1431-1434,4.基金项目
国家自然科学基金(30371336) （30371336）
